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Abstract
Objective To analyse clinical outcomes with new oral anticoagulants
for prophylaxis against venous thromboembolism after total hip or knee
replacement.
Design Systematic review, meta-analysis, and indirect treatment
comparisons.
Data sources Medline and CENTRAL (up to April 2011), clinical trials
registers, conference proceedings, and websites of regulatory agencies.
Study selection Randomised controlled trials of rivaroxaban, dabigatran,
or apixaban compared with enoxaparin for prophylaxis against venous
thromboembolism after total hip or knee replacement. Two investigators
independently extracted data. Relative risks of symptomatic venous
thromboembolism, clinically relevant bleeding, deaths, and a net clinical
endpoint (composite of symptomatic venous thromboembolism, major
bleeding, and death) were estimated using a random effect
meta-analysis. RevMan and ITC software were used for direct and
indirect comparisons, respectively.
Results 16 trials in 38 747 patients were included. Compared with
enoxaparin, the risk of symptomatic venous thromboembolism was lower
with rivaroxaban (relative risk 0.48, 95% confidence interval 0.31 to 0.75)
and similar with dabigatran (0.71, 0.23 to 2.12) and apixaban (0.82, 0.41
to 1.64). Compared with enoxaparin, the relative risk of clinically relevant
bleeding was higher with rivaroxaban (1.25, 1.05 to 1.49), similar with
dabigatran (1.12, 0.94 to 1.35), and lower with apixaban (0.82, 0.69 to
0.98). The treatments did not differ on the net clinical endpoint in direct
or indirect comparisons.
Conclusions A higher efficacy of new anticoagulants was generally
associated with a higher bleeding tendency. The new anticoagulants
did not differ significantly for efficacy and safety.
Introduction
Venous thromboembolism, which encompasses deep vein
thrombosis and pulmonary embolism, is responsible for the
death of more than half a million people in Europe each year
1
and is the third leading cause of death from cardiovascular
causes only ahead of myocardial infarction and stroke.
2
Additionally, 1.66 million cases of non-fatal symptomatic
venous thromboembolism are diagnosed in Europe each year,
with two thirds being acquired in hospital.
1 Venous
thromboembolism represents an important problem in patients
admitted to hospital, including those undergoing major
orthopaedic surgery.
3 4
The therapeutic arsenal of anticoagulants available for
prophylaxis against venous thromboembolism is mainly
composed of parenteral agents, such as low molecular weight
heparins or fondaparinux.
3 These agents are effective and safe
but require daily subcutaneous injections, which may be
problematic in some patients. Dabigatran etexilate (Pradaxa;
Boehringer Ingelheim International, Germany),
5 rivaroxaban
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Research
RESEARCH(Xarelto; Bayer Pharma, Germany),
6 and apixaban (Eliquis;
Bristol-MyersSquibb/PfizerEEIG,UnitedKingdom),
7arenew
oral anticoagulants available for prophylaxis against venous
thromboembolism in patients undergoing total hip or knee
replacement surgery. The pivotal studies on these indications
are mainly based on findings from mandatory venography of
the legs, which is not routinely carried out in standard practice.
Definitions for bleeding may differ between studies, however,
leadingtoanunderestimationofbleedingriskinsomecases.
8-10
Therefore the effect of the new oral anticoagulants on clinical
outcomes is uncertain. In addition, no up to date head to head
comparisons have been done between these new oral
anticoagulants.
We systematically reviewed and meta-analysed data from
randomised controlled trials of the new oral anticoagulants for
prophylaxis against venous thromboembolism in patients
undergoing total hip or knee replacement. We made direct
comparisonswithenoxaparinandindirectcomparisonsbetween
the new oral anticoagulants on the clinical outcomes of
symptomatic venous thromboembolism, bleeding, and death.
Methods
We considered randomised controlled trials comparing any of
theapprovedneworalanticoagulants(rivaroxaban,dabigatran,
and apixaban) with enoxaparin in patients undergoing total hip
or knee replacement. At least one of the daily doses tested in
the experimental arms had to correspond to the total daily dose
approved for the new oral anticoagulant (dabigatran 220 mg or
150 mg, apixaban 5 mg, or rivaroxaban 10 mg). At least one of
the daily doses tested in the control groups had to correspond
to the approved regimens for enoxaparin: 40 mg once daily
started 12 hours before surgery (Europe) or 30 mg twice daily
started 12-24 hours after surgery (North America).
Trial identification and data collection
We searched Medline and CENTRAL (up to April 2011),
clinical trial registries, relevant conference proceedings, and
websites of regulatory agencies (see supplementary file for
search strategy). No language restrictions were applied. Two
investigators (AG-O and AIT-F) independently and separately
assessed trials for eligibility and extracted data. If a trial was
covered in more than one report we used a hierarchy of data
sources: public reports from regulatory authorities (US Food
and Drug Administration, European Medicines Agency), peer
reviewed articles, reports from the web based repository for
results of clinical studies, and other sources. Finally, we
contacted sponsors or the main investigators for missing
outcome data.
Study characteristics and quality
To assess whether the trials were sufficiently homogeneous to
be meta-analysed we collected data on patients’ characteristics
(age and sex), percentage of patients evaluable for efficacy and
safety, dosage used in the experimental and control groups,
duration of treatment and follow-up, inclusion and exclusion
criteria, definitions of outcomes, adjudication committees of
venographies and clinical events, type of surgery (total hip or
knee replacement), and rate of events in the enoxaparin control
group. Additionally, we assessed study quality using the Jadad
scale.
11
Outcome measures
The prespecified primary outcome was symptomatic venous
thromboembolism—thatis,symptomaticdeepveinthrombosis
orsymptomaticpulmonaryembolism.Theprespecifiedprimary
safety outcome was clinically relevant bleeding—that is, major
bleeding or clinically relevant non-major bleeding. The main
secondaryoutcomeswereeachofthecomponentsoftheprimary
efficacy and safety outcomes, as well as all cause death and a
netclinicaloutcomeofhardendpoints,definedasthecomposite
ofsymptomaticvenousthromboembolism,majorbleeding,and
all cause death.
Other secondary outcomes included total venous
thromboembolism (venographic proximal or distal deep vein
thrombosisornon-fatalpulmonaryembolism)orallcausedeath
(composite main outcome in individual studies) and major
venous thromboembolism (venographic proximal deep vein
thrombosis or non-fatal pulmonary embolism) or venous
thromboembolism related death (composite key secondary
outcome in individual studies).
Statistical analysis
We carried out direct comparisons between dabigatran,
rivaroxaban,andapixabanversusenoxaparinaswellasindirect
comparisons between the three drugs on an intention to treat
basis, according to PRISMA (Preferred Reporting Items for
Systematic reviews and Meta-Analyses) recommendations.
12
For the meta-analysis we calculated relative risks and their
respective 95% confidence intervals for each study and for the
pooled studies for each of the anticoagulants. Heterogeneity
wasassessedusingtheCochranQtest
13andtheHigginsI
2test.
14
A Cochran’s Q P<0.10 and I
2 >50% were considered to show
significant heterogeneity.
14 We used the random effects model
described by Der-Simonian and Laird for the main analysis.
15
We carried out subgroup analyses of trials with the different
anticoagulants as well as in hip and knee replacement. P<0.05
for interaction indicates that the effect of treatment differs
between the tested subgroups. As a sensitivity analysis, we
calculated the results using the fixed effects method described
by Mantel and Haenszel.
16 Additional sensitivity analyses were
done taking into account certain methodological problems that
could influence the results of the meta-analysis: study phase,
study quality, and duration of thromboprophylaxis. We created
funnel plots showing the standard error and the effect size to
evaluate publication bias. Direct comparisons were done using
the RevMan statistical software, version 5.1 (Nordic Cochrane
Center).
17Forindirectcomparisons(Bucher’smethod),weused
the ITC (Indirect Treatment Comparison) computer program,
version 1.0.
18
Results
Theliteraturesearchidentified606articles,71ofwhichrelated
to clinical trials or protocols with rivaroxaban, dabigatran, or
apixaban (fig 1⇓). Of these, 19 were clinical trials in total hip
or knee replacement
19-37 and were selected for checking as full
text. Sixteen of the studies were eligible for inclusion
19-34 and
the remaining three,
35-37 all with dabigatran, were excluded
because they did not include a control group,
35 did not include
a dabigatran 150 mg or 220 mg daily dose group,
36 or used
placebo as control rather than enoxaparin.
37
Table 1⇓ shows the characteristics of the trials and treatments.
The 16 studies comprised 38 747 patients and compared
dabigatran (four studies),
19-22 rivaroxaban (eight studies),
23-30 or
apixaban (four studies)
31-34 with enoxaparin in total hip
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RESEARCHreplacement (eight studies)
20 22-24 27 29 30 33 or total knee
replacement (eight studies).
19 21 25 26 28 31 32 34 Of these, 36 149
patients were randomised to dosages of the new anticoagulant
(n=19 481) or control treatment (n=16 668) required for
inclusion in the meta-analysis and therefore comprised the
intention to treat population. Most of the studies (n=11) used
the European enoxaparin regimen as
comparator.
19 20 22-25 27 29 30 32 33 Three of the eight publications of
rivaroxaban trials did not include the specific method of
sequence generation,
27 29 30 and this information was obtained
from the sponsor after request. Fifteen of the 16 studies were
double blind clinical trials,
19-26 28-34 scoring 5 points (maximum
score) on the Jadad scale, and were judged to be at low risk of
bias (adequate sequence generation or allocation concealment,
double blinding, and clear reporting of loss to follow-up). The
remaining (dose finding) study with rivaroxaban scored 3
(because it was an open label study).
27 In all cases adjudication
of events was blinded.
Patients’ characteristics were homogeneous across the trials,
with age ranging between 61 and 68 years, a predominance of
women, and body weight between 75 and 84 kg (table 2⇓).
Rates of symptomatic venous thromboembolism in the
enoxaparin control group were low and similar across studies.
Thereforedataonsymptomaticvenousthromboembolismwere
consideredsuitableformeta-analysis.However,majorbleeding
rates reported in the four pivotal RECORD (Rosiglitazone
Evaluated for Cardiac Outcomes and Regulation of Glycaemia
in Diabetes) studies with rivaroxaban
23-26 were 7-8 times lower
than those in the enoxaparin groups of the remaining studies,
which was attributed to the exclusion of most wound bleedings
fromthedefinitionofmajorbleeding,aspreviouslyreported.
8-10
This issue prevented the pooling of data on major bleeding
reported in the publications of the RECORD studies. However,
the major bleeding rates in the RECORD studies without
excluding major wound bleedings were reported in an FDA
review,
38 and were similar to the major bleeding rates of the
remaining studies. Finally, we used the major bleeding data of
RECORDstudiesfromtheFDAinthemainanalysisandmajor
bleeding data from the publications as an additional sensitivity
analysis.
Primary efficacy outcome
Rivaroxaban was associated with a significant reduction in risk
of symptomatic venous thromboembolism compared with
enoxaparin (relative risk 0.48, 95% confidence interval 0.31 to
0.75; P=0.001) (fig 2⇓). Compared with enoxaparin, neither
dabigatran(0.71,0.23to2.12;P=0.54)norapixaban(0.82,0.41
to 1.64; P=0.57) reduced the risk of symptomatic venous
thromboembolism (fig 2).
Noevidenceofstatisticalheterogeneityforsymptomaticvenous
thromboembolism was found among studies comparing
rivaroxaban or apixaban with enoxaparin. However, there was
evidence of statistical heterogeneity for symptomatic venous
thromboembolismamongthedabigatrantrials(P=0.01;I
2=73%)
(fig2).Thesourceofheterogeneitycouldnotbeidentifiedafter
investigating dabigatran daily dose, enoxaparin regimen, type
ofsurgery,adjudicatingcommittee,orthepresenceofanoutlier
study. The effect on symptomatic venous thromboembolism
compared with enoxaparin was similar with dabigatran doses
of 220 mg (0.70, 0.18 to 2.76; P=0.61) and 150 mg (0.86, 0.31
to 2.35; P=0.63).
After including symptomatic venous thromboembolism events
that occurred during follow-up, the results were similar than
thoseofthemainanalysis(notincludingpost-treatmentevents):
rivaroxaban (0.53, 0.37 to 0.77; P=0.0008), dabigatran (0.90,
0.45to1.80;P=0.76),andapixaban(0.69,0.30to1.57;P=0.37)
compared with enoxaparin.
Secondary efficacy outcomes
Rivaroxaban was associated with a significantly lower risk of
symptomaticdeepveinthrombosisthanwasenoxaparin(relative
risk 0.40, 95% confidence interval 0.22 to 0.72; P=0.002),
whereas this trend was not significant for symptomatic
pulmonaryembolism(0.89,0.30to2.67;P=0.84).Rivaroxaban
also decreased the risk for total venous thromboembolism or
allcausedeath(0.56,0.39to0.80;P=0.002)aswellasformajor
venous thromboembolism or venous thromboembolism related
death (0.42, 0.21 to 0.86; P=0.02).
Comparedwithenoxaparin,dabigatranwasnotassociatedwith
adifferentriskofsymptomaticdeepveinthrombosis(0.82,0.17
to 3.99; P=0.81) or pulmonary embolism (0.69, 0.31 to 1.54;
P=0.36). Dabigatran was associated with a trend towards a
higher risk of total venous thromboembolism or all cause death
than enoxaparin (1.08, 0.93 to 1.25; P=0.31) and a similar risk
ofmajorvenousthromboembolismorvenousthromboembolism
related death (0.89, 0.63 to 1.25; P=0.49). The risk of total
venousthromboembolismorallcausedeathwassimilarbetween
dabigatran 220 mg and enoxaparin (1.00, 0.87 to 1.15; P=0.98)
but it was higher with the dabigatran 150 mg dose than with
enoxaparin (1.21, 1.05 to 1.39; P=0.009). Major venous
thromboembolism or venous thromboembolism related death
didnotdiffersignificantlybetweenthedabigatran220mgdaily
dose v enoxaparin (0.80, 0.54 to 1.17; P=0.24) or between the
dabigatran 150 mg daily dose v enoxaparin (1.12, 0.81 to 1.54;
P=0.49).
Apixaban decreased the risk of symptomatic deep vein
thrombosis compared with enoxaparin (0.41, 0.18 to 0.95;
P=0.04) but was associated with a numerical increase in cases
of pulmonary embolism (apixaban 24 v enoxaparin 14; relative
risk 1.25, 0.38 to 4.15; P=0.72) with borderline heterogeneity
(P=0.11; I
2=51%). The results for pulmonary embolism were
homogeneous within the two pivotal studies on total knee
replacement surgery (P=0.37; I
2=0%), in which the risk of
symptomatic pulmonary embolism with apixaban was
significantly higher than that with enoxaparin (2.56, 1.10 to
5.98; P=0.03). On the contrary, apixaban was associated with
alowerriskoftotalvenousthromboembolismorallcausedeath
(0.63, 0.42 to 0.95; P=0.03) and a trend towards a lower risk of
major venous thromboembolism or venous thromboembolism
relateddeath(0.61,0.32to1.14;P=0.12)thanenoxaparin.(See
supplementaryfiguresA1-7forthefullresultsofthesecondary
efficacy outcomes).
Primary safety outcome
Rivaroxaban was associated with a significant increase in risk
of clinically relevant bleeding (relative risk 1.25, 95%
confidence interval 1.05 to 1.49; P=0.01) (fig 3⇓). Dabigatran
did not show a significant increase compared with enoxaparin
(1.12, 0.94 to 1.35; P=0.21). The risk was similar in the
comparison of dabigatran 220 mg with enoxaparin (1.12, 0.92
to 1.38; P=0.26) and dabigatran 150 mg with enoxaparin (1.12,
0.89to1.40;P=0.34).Onthecontrary,apixabanwasassociated
with a significantly reduced risk of clinically relevant bleeding
compared with enoxaparin (0.82, 0.69 to 0.98; P=0.03). No
evidenceofstatisticalheterogeneitywasfoundforthisoutcome
among studies comparing rivaroxaban, dabigatran, or apixaban
with enoxaparin (fig 3).
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RESEARCHSecondary safety outcomes
Rivaroxabanwasassociatedwithanon-significanttrendtowards
a higher risk of major bleeding than was enoxaparin (relative
risk 1.29, 95% confidence interval 0.98 to 1.69; P=0.07) and
clinically relevant non-major bleeding (1.21, 0.98 to 1.50;
P=0.07).Comparedwithenoxaparin,dabigatranwasassociated
withasimilarriskofmajorbleeding(0.94,0.58to1.52;P=0.79)
and a non-significant trend towards a higher risk of clinically
relevant non-major bleeding (1.19, 0.96 to 1.48; P=0.11).
Apixaban showed a non-significant trend towards a low risk of
majorbleedingthandidenoxaparin(0.81,0.45to1.43;P=0.46),
which was in the limit of statistical significance for clinically
relevant non-major bleeding (0.83, 0.68 to 1.00; P=0.05). No
significant trends were found in risk of death between the new
anticoagulants and enoxaparin. (See supplementary figures
A8-10 for the full results of the secondary safety outcomes).
Net clinical endpoint
No statistically significant differences were found between the
new anticoagulants and enoxaparin on the net clinical endpoint
(symptomatic venous thromboembolism, major bleeding, and
death) (fig 4⇓). No evidence of statistical heterogeneity was
found between studies.
Main outcomes by type of surgery
No statistically significant interaction of the type of surgery
(total hip or knee replacement) was found for symptomatic
venous thromboembolism, clinically relevant bleeding, and net
clinical endpoint (table 3⇓). Overall, the net clinical benefit of
the new anticoagulants tended to be better in total knee
replacement surgery than in total hip replacement surgery.
Indirect comparisons
Rivaroxaban tended to be associated with the lowest risk for
symptomatic venous thromboembolism, whereas apixaban
seemedtoachievethelowestriskforclinicallyrelevantbleeding
(table 4⇓). No differences were found between treatments on
the net clinical outcome.
Absolute difference in events per 1000
patients treated
The numbers of symptomatic venous thromboembolic events
avoided per 1000 patients treated with rivaroxaban versus
enoxaparin, dabigatran, or apixaban were generally similar to
those of the additional resultant major bleeds (table 5⇓). No
significant absolute differences were apparent between
treatments on the net clinical outcome.
Sensitivity analyses
Sensitivity analyses were consistent with those of the main
analysis for the direct comparisons between the new
anticoagulants and enoxaparin on symptomatic venous
thromboembolism, clinically relevant bleeding, and the net
clinical endpoint, regardless of the assumption of the statistical
model and study quality, phase, or duration (see supplementary
tables A1-3). Acceptance of the definition for major bleeding
asreportedinthepublications(acceptingtheexclusionofmajor
wound bleedings in the RECORD studies), had a significant
impact on the apparent efficacy and safety of rivaroxaban, as it
would have been declared superior to enoxaparin in the net
clinical endpoint (0.68, 0.50 to 0.91; P=0.01) (table A4 of the
supplementary appendix). In sensitivity analyses of indirect
comparisons (tables A5 to A7 of the supplementary appendix),
the use of the fixed effects model led to closer confidence
intervals than those obtained using random effects, suggesting
a lower risk of symptomatic venous thromboembolism with
rivaroxabanthanwithdabigatran(0.53,0.29to0.99)orapixaban
(0.51, 0.27 to 0.96).
Publication bias
The visual inspection of funnel plots showed no evidence of
publication bias (see supplementary figure A11).
Role of funding
All studies were sponsored by pharmaceutical companies. The
sponsorwasresponsibleforthecollectionandstatisticalanalysis
of the data. In all cases the sponsor was involved in the design
and oversight of the study with or without the collaboration of
a scientific committee, and at least one of the authors of the
publications were employees of the sponsor.
Discussion
Thissystematicreviewandmeta-analysisindicatesthatahigher
efficacyofthenewtypeofanticoagulantisgenerallyassociated
with a higher bleeding tendency in patients undergoing total
hip or knee replacement surgery. At the time of balancing
efficacy (symptomatic venous thromboembolism) and safety
(major bleed and deaths), the different anticoagulants did not
differ significantly.
Rivaroxabanseemsmoreeffectivethanenoxaparininpreventing
symptomatic venous thromboembolism but at the cost of an
increase in clinically relevant bleeds. These results were
consistent across different studies, without evidence of
heterogeneity.
Dabigatran seems at least as effective as enoxaparin in the risk
of symptomatic venous thromboembolism, but the results are
noticeable by heterogeneity and wide confidence intervals.
Surrogate venographic data on major and total venous
thromboembolism indicates that the high dose (220 mg) is
consistently non-inferior to enoxaparin. The low dabigatran
dose (150 mg) may provide an alternative in patients with
anticipated increased exposure to dabigatran,
39 such as those
aged more than 75 years and those with moderate renal
impairment.
5Inourmeta-analysis,theriskofclinicallyrelevant
bleedingwasnotsignificantlydifferentbetweendabigatranand
enoxaparin. The upper limit of the 95% confidence interval,
however, indicates that a relative risk of clinically relevant
bleeding with dabigatran versus enoxaparin by 35% cannot be
excluded.
Apixabanwasassociatedwithalowerrateofclinicallyrelevant
bleeding than enoxaparin, mainly in knee pivotal studies, but
associated with an increase in cases of pulmonary embolism,
alsoinkneepivotalstudies.Symptomaticpulmonaryembolism
occurs earlier in knee replacement surgery than in hip
replacement surgery,
40 41 which might theoretically result in an
increase in risk of early pulmonary embolism if the first dose
of the anticoagulant is delayed. Whether the benefit in bleeding
and the numerical increase in pulmonary embolism in knee
studies are a chance finding or due to the delay of the first
apixaban dose about 18 hours after surgery (mean in pivotal
trials) deserves further scrutiny. Doctors may consider the
potential benefits of earlier anticoagulation for venous
thromboembolism prophylaxis as well as the risks of
post-surgicalbleedingindecidingonwhentoadministerwithin
the approved time window (12 to 24 hours after surgery for
apixaban).
7
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e3675 doi: 10.1136/bmj.e3675 (Published 14 June 2012) Page 4 of 16
RESEARCHOur meta-analysis also shows that the definition of major
bleeding may have a significant impact on the apparent safety
oftheanticoagulantsandthatevendifficulttoperceivechanges
in the definitions may lead to different conclusions in the
benefit-risk balance.
Strengths of the review
Our study represents the most comprehensive meta-analysis of
new oral anticoagulants carried out in total hip or knee
replacement surgery up to date. It is based on data from more
than 30 000 patients enrolled in 16 randomised clinical trials,
15 of them using a double blind design and all including an
independent and blinded assessment of outcomes. The studies
were published between 2005 and 2011 and evidence of
publication bias was lacking. Sensitivity analyses suggest that
theresultsarerobust.Itisunlikelythataclinicaltrialcomparing
two new oral anticoagulants in total hip or knee replacement
surgery would be carried out in the near future. Therefore our
resultsprovideausefulestimateofexpectedrelativedifferences
on clinically relevant events between rivaroxaban, dabigatran,
and apixaban in total hip or knee replacement surgery.
Comparison with other reports
Fewpreviousstudieshaveindirectlycompareddabigatranwith
rivaroxaban.
42-44 Only one of them indirectly compared rates of
symptomatic venous thromboembolism,
42 but it did not include
the RE-NOVATE II trial,
22 which was published afterwards.
One of these reports included studies with dabigatran,
rivaroxaban, and apixaban,
44 but the comparison was limited to
the endpoint of total venous thromboembolism plus all cause
death (mainly driven by asymptomatic venographic deep vein
thrombosis), and only pivotal trials were included. The study
showed better venographic outcomes with rivaroxaban and
apixaban than with dabigatran.
44
Limitations of the review
Our systematic review has limitations. The main efficacy
outcome in our study (symptomatic venous thromboembolism)
was a secondary outcome in all studies. Therefore the results
on symptomatic venous thromboembolism are exploratory.
Nevertheless, all events were adjudicated blindly and
independently, which adds robustness to the results obtained.
However, symptomatic venous thromboembolism events are
more representative of what would be expected in standard
clinical practice than are venographic (mainly asymptomatic)
events.
8 Direct comparisons between rivaroxaban or apixaban
versus enoxaparin for major or total venous thromboembolism
are based on studies in which venograms were adjudicated by
thesamecommittee(Gothenburgcommitteeintherivaroxaban
studies and Hamilton committee in the apixaban studies),
whereas two committees (Gothenburg and Holland) were used
in the dabigatran studies. Given the double blind adjudication,
it can be reasonably expected that the calculated relative risk
of direct comparisons would have provided an unbiased
estimate. However, we decided not to report indirect
comparisons on major and total venous thromboembolism
because the differences in venographic assessment reported
between different adjudicating committees
42 45 was considered
a factor that might bias the indirect comparison.
46
At the time of translating the results from these clinical trials
into practice, some considerations are necessary. In absolute
terms it is expected that patients in standard clinical practice
would have a higher risk for symptomatic venous
thromboembolism and bleeding than those included in clinical
trials, because of the exclusion criteria applied in clinical trials
(that is, severe renal or hepatic insufficiency, chronic use of
vitaminKantagonists,concomitanttreatmentwithnon-steroidal
anti-inflammatory drugs of long half life, strong CYP3A4
inhibitors, history of bleeding, and so on), as well as by other
differencesinpersonalcharacteristics.
47 48Itisworthmentioning
that the risk of bleeding increases with age and in other special
situations to a greater extent than does the risk of symptomatic
venous thromboembolism.
48 Therefore one of the main
uncertainties about the use of the new anticoagulants is related
to their real bleeding risk in standard clinical practice,
49-51 which
emphasises the need for appropriate use according to product
labelling to minimise such risk.
5-7
Conclusions
Our meta-analysis indicates that a higher efficacy of the new
type of anticoagulants was generally associated with a higher
bleeding tendency, but the anticoagulants did not differ
significantly for efficacy and safety.
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RESEARCHTables
Table 1| Characteristics of included randomised controlled trials and study treatments
Follow-up
(days)
Day of
venography
Jadad
score
Design of
randomised
Dose, treatment duration (timing of first dose in
relation to surgery)
Trial
phase
Type of
surgery
No in
sample Drug, trial
controlled
trial;
adjudicating
committee Control drug Experimental drug
Dabigatran:
90 6-10 5 Double blind;
Gothenburg
Enoxaparin 40 mg once
daily, 6-10 days (about 12
hours*)
Dabigatran 220 mg or 150
mg once daily, 6-10 days
(1-4 hours)
III Total knee
replacement
2101 RE-MODEL
19
94 33 5 Multicentre,
double blind;
Holland
Enoxaparin 40 mg once
daily, 28-35 days (aboout
12 hours*)
Dabigatran 220 mg or 150
mg once daily, 28-35 days
(1-4 hours)
III Total hip
replacement
3493 RE-NOVATE
20
90 14 5 Double blind;
Gothenburg
Enoxaparin 30 mg twice
daily, 12-15 days (12-24
hours)
Dabigatran 220 mg or 150
mg once daily, 12-15 days
(8-12 hours)
III Total knee
replacement
2615 RE-MOBILIZE
21
90 32 5 Double blind;
Holland
Enoxaparin 40 mg once
daily, 28-35 days (about
12 hours*)
Dabigatran 220 mg once
daily, 28-35 days (1-4
hours)
III Total hip
replacement
2055 RE-NOVATE II
22
Rivaroxaban:
66-71 36 5 Double blind;
Gothenburg
Enoxaparin 40 mg once
daily, 35 days (about 12
hours*)
Rivaroxaban 10 mg once
daily, 35d (6 hours)
III Total hip
replacement
4541 RECORD1
23
62-75 32-40 5 Double blind;
Gothenburg
Enoxaparin 40 mg once
daily, 14 days (about 12
hours*)+placebo 30 days
Rivaroxaban 10 mg once
daily, 31-39 days (6
hours)
III Total hip
replacement
2509 RECORD2
24
41-50 11-15 5 Double blind;
Gothenburg
Enoxaparin 40 mg once
daily, 10-14 days (about
12 hours*)
Rivaroxaban 10 mg once
daily, 10-14 days (6
hours)
III Total knee
replacement
2531 RECORD3
25
40-49 11-15 5 Double blind;
Gothenburg
Enoxaparin 30 mg twice
daily, 10-14 days (12-24
hours)
Rivaroxaban 10 mg once
daily, 10-14 days (6
hours)
III Total knee
replacement
3148 RECORD4
26
38-68 5-9 3 Open label;
Gothenburg
Enoxaparin 40 mg once
daily, 5-9 days (about 12
hours*)
Rivaroxaban 2.5, 5, 10,
20, or 30 mg twice daily,
rivaroxaban 30 mg once
daily, 5-9 days (6-8
hours)†
IIa Total hip
replacement
641 PROOF OF
CONCEPT
27
37-67 5-9 5 Double blind;
Gothemburg
Enoxaparin 30 mg twice
daily, 5-9days (12-24
hours)
Rivaroxaban 2.5, 5, 10,
20, or 30 mg twice daily,
5-9 days (6-8 hours)†
IIb Total knee
replacement
621 ODIXA KNEE
28
38-68 5-9 5 Double blind;
Gothenburg
Enoxaparin 40 mg once
daily, 5-9 days (about 12
hours*)
Rivaroxaban 2.5, 5, 10,
20, or 30 mg twice daily,
5-9 days (6-8 hours)†
IIb Total hip
replacement
722 ODIXA HIP
(twice daily)
29
35-69 6-10 5 Double blind;
Gothenburg
Enoxaparin 40 mg once
daily, 5-9 days (about 12
hours*)
Rivaroxaban 10, 20, or 30
mg once daily, 5-9 days
(6-8 hours)†
IIb Total hip
replacement
873 ODIXA HIP
(once daily)
30
Apixaban:
70-84 10-14 5 Double blind;
Hamilton
Enoxaparin 30 mg twice
daily, 12 days (12-24
hours)
Apixaban 2.5 mg twice
daily, 10-14 days (12-24
hours)
III Total knee
replacement
3195 ADVANCE-1
31
70-84 10-14 5 Double blind;
Hamilton
Enoxaparin 40 mg once
daily, 10-14 day (about 12
hours*)
Apixaban 2.5 mg twice
daily, 10-14 days (12-24
hours)
III Total knee
replacement
3057 ADVANCE-2
32
90-100 32-38 5 Double blind;
Hamilton
Enoxaparin 40 mg once
daily, 35 days (about 12
hours*)
Apixaban 2.5 mg twice
daily, 35 days (12-24
hours)
III Total hip
replacement
5407 ADVANCE-3
33
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RESEARCHTable 1 (continued)
Follow-up
(days)
Day of
venography
Jadad
score
Design of
randomised
controlled
trial;
adjudicating
committee
Dose, treatment duration (timing of first dose in
relation to surgery)
Trial
phase
Type of
surgery
No in
sample Drug, trial Control drug Experimental drug
42 10-14 5 Double blind;
Hamilton
Enoxaparin 30 mg twice
daily, 10-14 days (about
Apixaban 5, 10, or 20 mg
once daily, 2.5, 5, or 10
2b Total knee
replacement
1238 APROPOS
34
12 hours*) or warfarin mg twice daily, 10-14 days
(12-24 hours)‡ (international normalised
ratio 1.8-3.0§)
*Administered preoperatively; other first doses were administered postoperatively.
†Only data pertaining to 10 mg total daily dose (5 mg twice daily or 10 mg once daily) were included in the meta-analysis.
‡Only data pertaining to 5 mg total daily dose (2.5 mg twice daily or 5 mg once daily) were included in the meta-analysis.
§Only data pertaining to 40 mg once daily dose control group were included in the meta-analysis.
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RESEARCHTable 2| Characteristics of patients, surgery, and concomitant treatments*
Use of acetylsalicylic
acid/NSAID
Use of
intermittent Use of elastic
compression
stockings
Surgery
duration
(minutes)
Use of
neuraxial
anaesthesia
(%)
History of venous
thromboembolism
(%)
Participants mean
age (years), %
women, mean
weight (kg) Drug, trial
pneumatic
compression
Dabigatran:
Allowed: acetylsalicylic acid
<160 mg and NSAID of no
long half life
Prohibited Allowed 90 78 NA 68, 69, 82 RE-MODEL
19
Allowed: acetylsalicylic acid
<160 mg and NSAID of no
long half life
Prohibited Allowed 87 76 3 64, 56, 78 RE-NOVATE
20
Allowed: acetylsalicylic acid
<160 mg and NSAID if half
life <17 hours
Prohibited Allowed 90 48 NA 66, 58, 88 RE-MOBILIZE
21
NA Prohibited NA 79 77 2 62, 50, 80 RE-NOVATE II
22
Rivaroxaban:
Allowed Prohibited NA 91 70 2 63, 56, 78 RECORD1
23
Allowed Prohibited NA 93 71 1 62, 53, 75 RECORD2
24
Allowed Prohibited NA 97 79 4 68, 67, 81 RECORD3
25
Allowed Prohibited NA 100 81 2 65, 64, 84 RECORD4
26
Allowed if half life <17 hours Prohibited Allowed NA 73 NA 64, 54, 79 PROOF OF
CONCEPT
27
Allowed if half life <17 hours Prohibited Allowed 91 53 NA 66, 55, 89 ODIXA KNEE
28
Allowed if half life <17 hours Prohibited Allowed 82 70 NA 65, 59, 77 ODIXA HIP (twice
daily)
29
Allowed if half life <17 hours Prohibited NA 84 62 NA 66, 64, 75 ODIXA HIP (once
daily)
30
Apixaban:
Allowed if half life <17 hours NA NA 95 87 4 66, 62, 87 ADVANCE-1
31
Allowed if half life <17 hours NA NA 95 84 2 67, 74, 78 ADVANCE-2
32
Allowed if half life <17 hours NA NA 90 68 2 61, 55, 80 ADVANCE-3
33
NA NA NA 78 54 NA 67, 52, 83 APROPOS
34
NSAID=non-steroidal anti-inflammatory drug; NA=not available.
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RESEARCHTable 3| Symptomatic venous thromboembolism, clinically relevant bleeding, and net clinical endpoint by type of surgery
P value* Weight (%) Relative risk (95%CI)
No of events/No in group
Variables Enoxaparin New anticoagulant
Symptomatic venous thromboembolism
Dabigatran:
0.83 42.5 0.78 (0.05 to 12.35) 10/2181 23/3367 Hip
20 22
57.5 0.56 (0.16 to 1.98) 19/1575 25/3141 Knee
19 21
Rivaroxaban:
0.93 35.6 0.52 (0.18 to 1.45) 27/3990 11/3888 Hip
23 24 27 29 30
64.4 0.49 (0.29 to 0.83) 44/2946 21/2940 Knee
25 26 28
Apixaban:
0.14 23 0.40 (0.13 to 1.27) 10/2699 4/2708 Hip
33
77 1.08 (0.56 to 2.06) 23/3277 28/3437 Knee
31 32 34
Clinically relevant bleeding
Dabigatran:
0.36 51.8 1.22 (0.95 to 1.58) 87/2181 178/3367 Hip
20 22
48.2 1.01 (0.74 to 1.39) 79/1575 162/3141 Knee
19 21
Rivaroxaban:
0.90 59.6 1.25 (0.90 to 1.75) 152/3990 186/3888 Hip
23 24 27 29 30
40.4 1.29 (0.99 to 1.67) 96/2946 123/2940 Knee
25 26 28
Apixaban:
0.09 52.2 0.95 (0.75 to 1.19) 138/2699 131/2708 Hip
33
47.8 0.71 (0.55 to 0.91) 143/3277 103/3437 Knee
31 32 34
Net clinical endpoint
Dabigatran:
0.06 49.3 1.26 (0.80 to 1.98) 38/2181 81/3367 Hip
20 22
50.7 0.71 (0.48 to 1.05) 41/1575 58/3141 Knee
19 21
Rivaroxaban:
0.76 53.2 0.92 (0.60 to 1.41) 94/3990 86/3888 Hip
23 24 27 29 30
46.8 0.85 (0.60 to 1.19) 84/2946 71/2940 Knee
25 26 28
Apixaban:
0.70 32.8 1.00 (0.60 to 1.66) 29/2699 29/2708 Hip
33
67.2 0.88 (0.62 to 1.26) 62/3277 58/3437 Knee
31 32 34
*Random effects model, subgroup differences.
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RESEARCHTable 4| Indirect comparisons between rivaroxaban, dabigatran, and apixaban*
Relative risk (95% CI)
Outcomes Apixaban v dabigatran Rivaroxaban v apixaban Rivaroxaban v dabigatran
1.16 (0.31 to 4.28) 0.59 (0.26 to 1.33) 0.68 (0.21 to 2.23) Symptomatic venous thromboembolism
0.73 (0.57 to 0.94) 1.52 (1.19 to 1.95) 1.12 (0.87 to 1.44) Clinically relevant bleeding
0.86 (0.41 to 1.83) 1.59 (0.84 to 3.02) 1.37 (0.79 to 2.39) Major bleeding
0.99 (0.61 to 1.61) 0.96 (0.66 to 1.40) 0.95 (0.61 to 1.48) Net clinical endpoint
*Random effects model, events while receiving treatment.
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RESEARCHTable 5| Direct and indirect comparisons: absolute difference in events per 1000 patients treated*
Risk difference (95% CI)
Comparison Net clinical endpoint Major bleeding Clinically relevant bleeding Symptomatic venous thromboembolism
Direct comparisons:
−3 (−9 to 3) 4 (−0.4 to 8) 9 (2 to 17) −5 (−9 to −1) Rivaroxaban v enoxaparin
−1 (−9 to 7) −1 (−6 to 5) 5 (−4 to 13) −2 (−9 to 5) Dabigatran v enoxaparin
−1 (−6 to 3) −1 (−7 to 5) −8 (−15 to −1) −1 (−4 to 2) Apixaban v enoxaparin
Indirect comparisons:
−2 (−12 to 9) 4 (−2 to 11) 5 (−7 to 16) −3 (−11 to 4) Rivaroxaban v dabigatran
−2 (−9 to 6) 5 (−2 to 12) 18 (7 to 28) −4 (−9 to 1) Rivaroxaban v apixaban
0 (−9 to 9) 0 (−8 to 7) −13 (−24 to −2) 1 (−7 to 8) Apixaban v dabigatran
*Random effects model, events while receiving treatment.
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RESEARCHFigures
Fig 1 Study identification, selection, and exclusions
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RESEARCHFig 2 Symptomatic venous thromboembolism
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RESEARCHFig 3 Clinically relevant bleeding
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RESEARCHFig 4 Net clinical endpoint
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